WOCKHARDT LTD.

Wockhardt Ltd. announced that the U.S. FDA has approved ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic, for treating adult patients with complicated urinary tract infections (cUTI), including pyelonephritis. ZAYNICH™ demonstrated a higher combined clinical cure and microbiologic response compared to meropenem in the Phase 3 ENHANCE-1 clinical trial (89.0% vs 68.4%). It is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive FDA approval.

Wockhardt Ltd. announced that the Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorization for its breakthrough antibiotic, ZAYNICH® (Zidebactam/Cefepime), in India. This approval is for treating complicated urinary tract infections (cUTI) in adults, including pyelonephritis with concurrent Gram-negative bacteremia. The authorization is supported by the pivotal ENHANCE-1 Phase 3 clinical trial, where ZAYNICH® demonstrated statistical superiority over meropenem, achieving the primary endpoint in 89% of patients compared to 68.4% for meropenem. ZAYNICH® is crucial for addressing metallo-β-lactamase (MBL)-mediated resistance and extensively drug-resistant (XDR) Gram-negative pathogens, offering a vital therapeutic option where current treatments are limited by toxicity or suboptimal efficacy. Submissions for New Drug Application (NDA) in the US and Marketing Authorisation Application (MAA) in the EU are also underway.

Wockhardt Ltd's monitoring agency report for the quarter ended March 31, 2026, confirms no deviation in the utilization of Qualified Institutions Placement (QIP) proceeds from the objects stated in the Placement Document dated November 11, 2024. CRISIL Ratings Limited issued the report, which was reviewed and taken on record by the Board of Directors & Audit Committee. The QIP issue period was from November 6, 2024, to November 11, 2024, with gross proceeds of ₹1,000.00 crores and net proceeds of ₹977.79 crores.

Wockhardt Ltd has announced the appointment of Ms. Annapurna Das, Mr. Om Narayan, and Mr. Sunil Soni as Senior Management Personnel, effective May 4, 2026. The decision was made during the Board of Directors meeting. Ms. Das will serve as President (India Business & Emerging Markets (NCE)), Mr. Narayan as Senior Vice President (Biotech Research Centre), and Mr. Soni as Senior Vice President (Biotechnology). Details of their profiles and terms are disclosed in the filing.

Wockhardt Ltd reported a positive Profit Before Tax (PBT) of ₹238 Cr for FY26, a significant improvement from a loss of ₹16 Cr in the previous year. The company's Q4 FY26 revenue grew by 30% to ₹965 crore, with EBITDA up by 147% to ₹196 Cr. For the full year, revenue increased by 11% to ₹3373 crore, and EBITDA grew by 51% to ₹630 Cr. Biosimilar operations showed strong growth, with a 126% increase in Q4 and 27% for the full year. India branded business grew by 18% in Q4 and 15% for the full year.

Wockhardt Ltd's Board of Directors approved the audited financial results (standalone & consolidated) for the quarter and financial year ended March 31, 2026. The board also approved enabling proposal for raising funds through various methods, subject to shareholder approval. The meeting concluded at 3:10 p.m. on May 4, 2026.

Wockhardt Ltd's Board of Directors approved the audited financial results (standalone & consolidated) for the quarter and financial year ended March 31, 2026. The board also approved enabling proposal for raising funds through the issuance of equity shares or other securities. The meeting commenced at 11:00 a.m. and concluded at 3:10 p.m.

Wockhardt Ltd. has scheduled a Board Meeting for Monday, May 4, 2026. The primary agenda includes considering and approving the Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2026. Additionally, the Board will discuss and approve a proposal to raise funds through various instruments. These instruments may include Equity Shares, Global Depository Receipts (GDRs), American Depository Receipts (ADRs), Foreign Currency Convertible Bonds (FCCBs), and other convertible or non-convertible securities. The fund-raising could be executed through public or private offerings, including Qualified Institutions Placement (QIP) or preferential allotment, subject to shareholder approval. In compliance with insider trading regulations, the trading window for designated persons closed on April 1, 2026, and will reopen 48 hours after the financial results are declared.

Wockhardt Limited has announced that its novel antibiotic, Zaynich (Zidebactam/Cefepime), has received a favourable recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for the treatment of Gram-negative infections. This positive opinion brings Zaynich closer to final approval by the Drugs Controller General of India (DCGI). The recommendation follows a comprehensive review of the product dossier, including non-clinical data, nine Phase 1 studies, a multi-indication Phase 2 study in meropenem-resistant infections, a global Phase 3 study in complicated urinary tract infections and acute pyelonephritis, and data from 85 compassionate-use cases. Zaynich, developed over 15 years, features a novel β-lactam enhancer-based mechanism, potentially offering unprecedented coverage of MDR/XDR Gram-negative pathogens prevalent in India. It is one of the most comprehensively evaluated antibiotics globally in recent years, with over 100 national and international publications and presentations. Zaynich has demonstrated superiority over meropenem in combined clinical and microbiological cure in the Phase 3 study, and showed over 97% clinical efficacy in a real-world study of meropenem-resistant infections in India. It also demonstrated strong efficacy in 85 XDR Gram-negative infection cases treated under compassionate use in India, US, Malaysia, and France. A New Drug Application (NDA) in the United States and a Marketing Authorisation Application (MAA) in the European Union for Zidebactam/Cefepime have been submitted and are currently in the advanced stages of review.

Wockhardt Ltd has been assigned an ESG rating of 65 (Aspiring) for the year 2025 by NSE Sustainability Ratings and Analytics Limited. The rating is based on the Company's public disclosures and other publicly available information. The score comprises 51 for Environmental, 70 for Social, and 74 for Governance parameters. The Company has not engaged NSE Sustainability Ratings for this purpose and the rating is independently determined by them.